AbbVie Tops Q3 Estimates, Raises 2026 EPS Guidance and Lifts Dividend 5.2%
ABBV sits 49% above its 52-week low of $190.75.
Summary
AbbVie reported Q3 2026 revenue of $17.404 billion (+10.3%) and adjusted EPS of $3.82, raised 2026 adjusted EPS guidance to $13.95-$13.99 and its 2026 revenue forecast to $67.8 billion from $67.6 billion, and increased its quarterly dividend 5.2% to $1.82.
Updated with a Benzinga report · What changed
Updates
· Benzinga — AbbVie raised its 2026 revenue forecast to $67.8 billion from $67.6 billion, with Skyrizi at $21.8 billion and Rinvoq at $10.3 billion.
Key Events · Earnings and Guidance · ABBV
-
Updated · · Benzinga
2026 EPS Guidance Raised, Revenue Forecast Lifted
Full-year adjusted diluted EPS guidance moves to $13.95-$13.99 from $13.76-$13.96, including a $0.69 per-share year-to-date IPR&D and milestones impact. The 2026 revenue forecast was raised to $67.8 billion from $67.6 billion, with Skyrizi at $21.8 billion and Rinvoq at $10.3 billion.
-
Q3 Revenue Up 10.3% to $17.4B
Worldwide net revenues reached $17.404 billion, up 10.3% reported and 10.5% operational, with immunology contributing $9.165 billion (+16.3%).
-
Adjusted EPS More Than Doubles
GAAP diluted EPS was $2.37 versus $0.10 a year ago, while adjusted diluted EPS was $3.82 versus $1.86, including a $0.11 per-share hit from acquired IPR&D and milestones.
-
Dividend Raised 5.2% to $1.82
The board declared a quarterly dividend of $1.82 per share, up from $1.73, payable February 16, 2027 to holders of record January 15, 2027.
Analysis · ABBV · Life Sciences
Revenue of $17.404 billion rose 10.3% in the third quarter, and adjusted EPS of $3.82 more than doubled from $1.86. Skyrizi ($5.776B, +22.7%) and Rinvoq ($2.706B, +23.9%) drove the growth, offsetting Humira's 31.2% decline. Management raised full-year adjusted EPS guidance to $13.95-$13.99, lifted the 2026 revenue forecast to $67.8 billion from $67.6 billion with Skyrizi at $21.8 billion and Rinvoq at $10.3 billion, and lifted the quarterly dividend 5.2% to $1.82, while the Apogee acquisition has now closed. For a $500B+ pharma trading near its 52-week high, the guidance raise, higher revenue forecast and dividend increase support the earnings-growth thesis rather than change it.
How filings like this one have moved
In the 30 days to Oct 30, 2026, 38.3% of the 891 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.41%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ABBV was trading at $285.00 on NYSE in the Life Sciences sector, with a market capitalization of approximately $513.9B. The 52-week trading range was $190.75 to $292.67. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.